Cosentyx Part IIIb Information Utilizing UnoReady for Psoriasis

Novartis Releases Part IIIb Information for its UnoReady Pen with Cosentyx (secukinumab)

Appointment:

---

Novartis right this moment introduced knowledge from a global part IIIb examine, which confirmed that remedy with Cosentyx® (secukinumab) 300 mg in a 2 ml autoinjector (UnoReady® pen) resulted in excessive efficacy and handy administration in adults with psoriasis. in average to extreme plaques1. These knowledge have been introduced on the thirtieth Anniversary Congress of the European Academy of Dermatology and Venereology (EADV).

“Continual ailments like psoriasis can typically be troublesome to handle and adherence to therapies could be difficult for sufferers,” stated Professor Bardur Sigurgeirsson of the College of Iceland, lead creator of the MATURE examine. “This examine reveals {that a} 300 mg dose of Cosentyx could be given in a single injection, making it extra handy and simpler for sufferers to make use of, with out compromising efficacy or security.”

The MATURE examine evaluated the usage of one 300 mg Cosentyx autoinjector versus two 150 mg pre-filled syringes or placebo. Sufferers utilizing the 300 mg autoinjector reported a big enchancment in pores and skin clearance as measured by Psoriasis Space and Severity Index (PASI) 75 and 90 in comparison with placebo.

“We’re at all times searching for methods to enhance the usability and adherence of all our therapies, so that individuals get essentially the most profit and the therapies are handy to manage. With the Cosentyx 300 mg autoinjector, individuals with psoriasis can higher management their signs with fewer injections. It is nice to know that each one the adults who tried the Cosentyx UnoReady autoinjector stated they have been happy with the way it labored, ”stated Todd Fox, International Medical Affairs Director for Immunology, Hepatology and Dermatology at Novartis.

The examine confirmed excessive affected person satisfaction, with 100% of these within the Cosentyx 300 mg UnoReady group reporting that they have been “very happy” or “happy” at week 28. The reported security profile was per earlier research, and no new security indicators have been detected. noticed.

The UnoReady pen was authorized to be used in Europe in November 2020 for all sufferers requiring a 300 mg dose of Cosentyx. Cosentyx is authorized in additional than 100 international locations in doses as much as 300 mg for adults with average to extreme plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Supply: novartis.com

Secukinumab – Cosentyx

(Solar-03-10-2021, 03:29 AM)KatT wrote: After all!!! I do not suppose anybody prefers two injections to at least one!

I might quite have two syringes than an autoinjector.

You are masochistic !!!!!

However would you quite have one or two autoinjectors ????

(Solar-03-10-2021, 21:30 PM)KatT wrote: You are masochistic !!!!!

However would you quite have one or two autoinjectors ????

None I do not like auto-injectors. I’ve by no means had an issue with syringes, they’re so easy.